• Twitter Clean

© 2020 Medtech & Pharma Platform

Pharma and medtech innovation in times of societal, technological and regulatory shifts

Speaker Program Day 1


Conference opening

Shayesteh Fürst-Ladani, President MPP association


Welcome address

State Councillor Christoph Brutschin, Head of the Department of Economics, Social and Environmental Affairs of the Canton Basel-City


Keynote: Digital healthcare solutions – from big data to clinical impact

Hans Hofstraat, Philips Research, Philips


Session 1 - Medical applications enabled by new technology

Chair: Michel Dard, Straumann

A platform for innovation

Stefano Mallé, Microsoft

Quantum computing in life sciences & healthcare

Frederik Flöther, IBM

Building Trust – Artificial Intelligence from the user’s point of view

Sibylle Peuker, Zeix AG

Quality 4.0 and Medtech applications

Bieke Smeuninx, Nikon


Session 2 - Open innovation within ecosystems

Chair: Clotilde Aubertin-Jordan, GSK

Emerging opportunities with Digital Therapeutics

Andrew Koubatis, Altran

Digital Heathcare Ecosystems – the steps & success factors for digital business models and ecosystems

Daniel Ochs, Detecon

Transactional Pharma - Building a data ecosystem in healthcare

Katina Sostmann, Aperto

Strategic plan mitigations for medical device companies under EU-MDR

Ella Dehghani, EY


Session 3 - Are new regulations going to slow down innovation?

Chair: Karin Schulze, SFL

Status of the Medical Device Regulation

Bassil Akra, TÜV SUD

The future regulatory framework in Switzerland

Bernhard Bichsel, Swissmedic

Auto-injector Case study: Navigating a safe course through the EU Medical Device Regulation

Elodia Di Renzo, Roche

Reimagining the relationship between regulation and innovation

Deepa Rajagopalan, Tao of Excellence

Speaker Program Day 2


Conference opening

Peter Biedermann, Member Board of Directors MPP


Keynote: Digital Health the interplay between software and medicine

Sam Shah, NHS Consultant and Clinical Informatician, NHSX


Session 4 - New regulations and implications for software and digital health

Chair: Dorit Prüfer, Roche

The Regulatory Trend and the Application of Digital Health

Pei-Ting Sarah Chou, RAPS Taiwan

MDR Rule 11 – influencing software identified as medical devices with full force

Stefan Krieg, DHC AG

Regulatory and data protection considerations using software as medical device (SaMD) in drug development

Theresa Jeary, SFL


Session 5 - From development to market and back

Chair: Andy Tonazzi, konplan systemhaus

MedTech vs. Apple, Google & Co. – an irresolvable clash of cultures?

Boris Langer, Zühlke

Innovate the experience, not just the product: impact of the innovation partnership in all stages and along the end to end process

Clotilde Aubertin-Jordan, GSK 

Additive Manufacturing meets Pharma & Medtech: A Strategic Patent Analysis

Anna Maria Villa, IGE/IPI

Regulatory impacts on startup innovation in Digital Healthcare

Faraz Oloumi, Aurteen & Christian Vogler, Advancience


Session 6 - Precision medicines and patient perspective

Chair: Jürg Leemann, Ypsomed

Early stage development strategies for identifying unmet user needs for a connected device

Michael Brookes, Novartis

Exploring the limit of large-volume subcutaneous dosing: How far can we go with hand-held autoinjectors?

Andreas Schneider, Ypsomed

The IASO wearable

Guillaume Kerboul, Dassault Systèmes

#WeAreNotWaiting: Closing the loop ourselves

Edward Oakeley & Andrew Warrington, Patient Advocates